|
Brentuximab vedotin (BV) consolidation post-autologous stem cell transplant (ASCT) in patients (pts) with Hodgkin lymphoma (HL) at risk of residual disease: Number needed to treat (NNT) analysis. |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Takeda |
|
|
|
|
|
|
Stock and Other Ownership Interests - Takeda |
|
|
|
|
|
Employment - AmerisourceBergen; Millennium |
Stock and Other Ownership Interests - AmerisourceBergen; Takeda |
|
|
|
Stock and Other Ownership Interests - Seagen |
Research Funding - Seagen |
Travel, Accommodations, Expenses - Seagen |
|
|
|
Stock and Other Ownership Interests - Amgen; Seagen |
|
|
|
Stock and Other Ownership Interests - Takeda |